• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Experience with the Vero cell line.

作者信息

Montagnon B J, Vincent-Falquet J C

机构信息

Pasteur Mérieux Sérums & Vaccins, Marcy L'Etoile, France.

出版信息

Dev Biol Stand. 1998;93:119-23.

PMID:9737386
Abstract

The Vero cell line has been managed with the Cell Bank system to produce at the 142nd passage IPV, OPV and rabies vaccines since 1982 by Pasteur Mérieux Serums & Vaccins (PMsv). The safety of the cell line was regularly validated at the Working Cell Bank (WCB) level according to the WHO and European Pharmacopoeia requirements for absence of bacteria, fungi, mycoplasma and viruses. A special emphasis was devoted to research on the absence of simian viruses (SV40, SIV, Retro-D virus and simian CMV). All these specific researches were negative. At a low level of passage, the Vero cells are not tumorigenic. Vaccines have been prepared in low passage level Vero cells and together with the excellent downstream purification have resulted in excellent safety as attested by pharmacovigilance of more than 100 million doses of IPV during 12 years, more than 20 million doses of rabies vaccine during 10 years and more than 1 billion of OPV during eight years.

摘要

相似文献

1
Experience with the Vero cell line.
Dev Biol Stand. 1998;93:119-23.
2
Experience with vero cells at Pasteur Mérieux Connaught.
Dev Biol Stand. 1999;98:137-40; discussion 167.
3
Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line.在连续传代细胞系中生产的脊髓灰质炎疫苗和狂犬病疫苗:Vero细胞系的实际应用
Dev Biol Stand. 1989;70:27-47.
4
Systematically experimental investigation on carcinogenesis or tumorigenicity of VERO cell lines of different karyotypes in nude mice in vivo used for viral vaccine manufacture.对用于生产病毒疫苗的不同核型VERO细胞系在裸鼠体内的致癌性或致瘤性进行系统的实验研究。
Yi Chuan Xue Bao. 2004 Jul;31(7):647-60.
5
Qualification of working cell banks for the Vero cell line to produce licensed human vaccines.
Dev Biol Stand. 1989;70:153-6.
6
Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV).一种新型经色谱纯化的Vero细胞狂犬病疫苗(CPRV)在成人中的免疫原性和安全性:一项与纯化Vero细胞狂犬病疫苗(PVRV)对比的随机双盲试验。
Biologicals. 1998 Dec;26(4):299-308. doi: 10.1006/biol.1998.0156.
7
Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs.在Vero细胞、MDCK细胞和鸡胚中培养的流感病毒的生长及免疫原性。
Dev Biol Stand. 1999;98:39-51; discussion 73-4.
8
A rabies vaccine produced in a non-tumorigenic rabbit cell line.一种在非致瘤性兔细胞系中生产的狂犬病疫苗。
Dev Biol Stand. 1985;60:133-9.
9
Suspension-Vero cell cultures as a platform for viral vaccine production.悬浮Vero细胞培养作为病毒疫苗生产的平台。
Vaccine. 2009 Oct 30;27(46):6464-7. doi: 10.1016/j.vaccine.2009.06.020. Epub 2009 Jun 24.
10
Immunogenicity and safety of a new Vero cell rabies vaccine produced using serum-free medium.使用无血清培养基生产的新型Vero细胞狂犬病疫苗的免疫原性和安全性。
Vaccine. 2007 Nov 23;25(48):8140-5. doi: 10.1016/j.vaccine.2007.09.043.

引用本文的文献

1
Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis.通过拓扑异构酶抑制、细胞周期阻滞和细胞凋亡设计和合成新型细胞毒性氟喹诺酮类似物。
Sci Rep. 2023 Mar 13;13(1):4144. doi: 10.1038/s41598-023-30885-5.
2
The C-Terminal 300 Amino Acid Residues of the G Protein and Putative Open Reading Frame X of the G Gene of Tailam Paramyxovirus (TlmPV) Are Not Required for Replication in Tissue Culture Cells.尾黏液瘤病毒(TlmPV)G 蛋白和推定开放阅读框 X 的 C 端 300 个氨基酸残基对于在组织培养细胞中的复制并非必需。
J Virol. 2023 Jan 31;97(1):e0180222. doi: 10.1128/jvi.01802-22. Epub 2022 Dec 15.
3
Poliovirus-nonsusceptible Vero cell line for the World Health Organization global action plan.
用于世界卫生组织全球行动计划的对脊髓灰质炎病毒不敏感的vero 细胞系。
Sci Rep. 2021 Mar 24;11(1):6746. doi: 10.1038/s41598-021-86050-3.
4
Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2.奥美拉唑增强阿昔洛韦对1型和2型单纯疱疹病毒的疗效。
Front Microbiol. 2019 Dec 3;10:2790. doi: 10.3389/fmicb.2019.02790. eCollection 2019.
5
Novel endogenous simian retroviral integrations in Vero cells: implications for quality control of a human vaccine cell substrate.新型内源性猴内源性逆转录病毒整合到 Vero 细胞中:对人用疫苗细胞基质质量控制的影响。
Sci Rep. 2018 Jan 12;8(1):644. doi: 10.1038/s41598-017-18934-2.
6
Product review on the JE vaccine IXIARO.关于日本脑炎疫苗IXIARO的产品综述。
Hum Vaccin Immunother. 2015;11(2):411-20. doi: 10.4161/21645515.2014.983412.
7
Matrix and backstage: cellular substrates for viral vaccines.基质与后台:病毒疫苗的细胞底物
Viruses. 2014 Apr 11;6(4):1672-700. doi: 10.3390/v6041672.
8
A serum-free Vero production platform for a chimeric virus vaccine candidate.无血清 Vero 细胞生产平台用于生产嵌合病毒候选疫苗。
Cytotechnology. 2006 Jul;51(3):183-92. doi: 10.1007/s10616-006-9030-7. Epub 2006 Nov 16.
9
The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery.利用荧光显微镜确定聚合物在作为药物递送靶点的细胞晚期内吞小室中的定位。
J Control Release. 2008 Apr 7;127(1):1-11. doi: 10.1016/j.jconrel.2007.12.015. Epub 2008 Jan 4.
10
Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.用副流感病毒2型(PIV2)的对应结构域替换重组3型副流感病毒(PIV3)血凝素神经氨酸酶和融合糖蛋白的胞外结构域,可产生减毒的PIV2候选疫苗。
J Virol. 2000 Jul;74(14):6448-58. doi: 10.1128/jvi.74.14.6448-6458.2000.